Medivation Inc

Most Recent

  • uploads///acquisition
    Company & Industry Overviews

    Medivation Is for Sale: How Much Should It Get?

    Considering the prospects for the pipeline, Medivation should get more than what Sanofi offered. It will probably get more than what Pharmacyclics received.

    By Jillian Dabney
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • uploads///PE and share price
    Company & Industry Overviews

    Pfizer’s Medivation Acquisition: What You Need to Know

    On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.

    By Jillian Dabney
  • uploads///operating segments
    Earnings Report

    A Look at Mallinckrodt’s Operating Segments

    Mallinckrodt (MNK) is a specialty pharmaceuticals company that relies on volume-driven growth. Let’s discuss the performances of its three segments.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    A Look at the Pfizer-Medivation Deal

    Pfizer-Medivation deal On September 27, 2016, Pfizer (PFE) completed the acquisition of Medivation (MDVN). The stock transaction is valued at $81.50 per Medivation share, resulting in a total enterprise value of ~$14 billion. What is Medivation? Medivation is a California-based biopharmaceutical company. It is focused on developing and commercializing innovative therapies for the treatment of […]

    By Mike Benson
  • uploads///Orkambi
    Company & Industry Overviews

    Higher Discontinuations Are among Orkambi’s Concerns

    Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares to Its Peers

    Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.

    By Mike Benson
  • uploads///margins
    Earnings Report

    Can Mallinckrodt Expand Its Margins?

    Wall Street analysts expect Mallinckrodt’s (MNK) net margin to jump to 24.3% in 3Q16 from 10% in 3Q15.

    By Jillian Dabney
  • uploads///dupilumab
    Earnings Report

    Regeneron’s Dupilumab: How Much Potential Does It Hold?

    Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.

    By Jillian Dabney
  • uploads///xtandi duration
    Earnings Report

    Could Medivation’s Xtandi Become a Major Urology Drug?

    Although Medivation’s (MDVN) Xtandi is a leader in the oncology space, it has significant opportunity in the urology space as well.

    By Jillian Dabney
  • uploads///Xtandi opporunity
    Company & Industry Overviews

    Opportunities For Xtandi, Medivation’s Key Drug

    Enzalutamide, known by its brand name Xtandi, is an androgen receptor inhibitor. It is the only commercialized product in Medivation’s (MDVN) portfolio.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals: Valuation Compared to Its Peers

    In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

    By Mike Benson
  • uploads///Graph Part
    Company & Industry Overviews

    Medivation and Bluebird Led IBB’s Mid-Cap Stocks Last Week

    Medivation and Bluebird led IBB’s mid-cap stocks for the week ended September 18, 2015.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.